## As Passed by the House

## 131st General Assembly

# Regular Session

Am. H. B. No. 188

2015-2016

### Representatives Manning, Huffman

Cosponsors: Representatives Maag, Rezabek, Gonzales, Amstutz, Anielski, Antonio, Baker, Blessing, Boyce, Boyd, Buchy, Burkley, Conditt, Craig, Derickson, Dever, Dovilla, Gerberry, Ginter, Green, Hackett, Hall, Hambley, Hayes, Howse, Kraus, Kuhns, Leland, McClain, O'Brien, M., Patterson, Pelanda, Perales, Ramos, Reece, Retherford, Rogers, Ryan, Schaffer, Scherer, Sears, Sheehy, Slaby, Smith, R., Stinziano, Strahorn, Terhar, Young, Speaker Rosenberger

#### A BILL

То	amend sections 4729.01, 4729.281, and 4729.39 of	1
	the Revised Code to revise the laws governing	2
	pharmacist consult agreements and the laws	3
	governing the circumstances under which a	4
	pharmacist may dispense or sell a drug without a	5
	prescription.	6

#### BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That sections 4729.01, 4729.281, and 4729.39 of	7
the Revised Code be amended to read as follows:	8
Sec. 4729.01. As used in this chapter:	9
(A) "Pharmacy," except when used in a context that refers	10
to the practice of pharmacy, means any area, room, rooms, place	11
of business, department, or portion of any of the foregoing	12
where the practice of pharmacy is conducted.	13
(B) "Practice of pharmacy" means providing pharmacist care	14

requiring specialized knowledge, judgment, and skill derived	15
from the principles of biological, chemical, behavioral, social,	16
pharmaceutical, and clinical sciences. As used in this division,	17
"pharmacist care" includes the following:	18
(1) Interpreting prescriptions;	19
(2) Dispensing drugs and drug therapy related devices;	20
(3) Compounding drugs;	21
(4) Counseling individuals with regard to their drug	22
therapy, recommending drug therapy related devices, and	23
assisting in the selection of drugs and appliances for treatment	24
of common diseases and injuries and providing instruction in the	25
proper use of the drugs and appliances;	26
(5) Performing drug regimen reviews with individuals by	27
discussing all of the drugs that the individual is taking and	28
explaining the interactions of the drugs;	29
(6) Performing drug utilization reviews with licensed	30
health professionals authorized to prescribe drugs when the	31
pharmacist determines that an individual with a prescription has	32
a drug regimen that warrants additional discussion with the	33
prescriber;	34
(7) Advising an individual and the health care	35
professionals treating an individual with regard to the	36
<pre>individual's drug therapy;</pre>	37
(8) Acting pursuant to a consult agreement with $\frac{a}{a}$	38
physician one or more physicians authorized under Chapter 4731.	39
of the Revised Code to practice medicine and surgery or	40
osteopathic medicine and surgery, if an agreement has been	41
established with the physician;	42

(9) Engaging in the administration of immunizations to the	43
extent authorized by section 4729.41 of the Revised Code.	44
(C) "Compounding" means the preparation, mixing,	45
assembling, packaging, and labeling of one or more drugs in any	46
of the following circumstances:	47
(1) Pursuant to a prescription issued by a licensed health	48
professional authorized to prescribe drugs;	49
(2) Pursuant to the modification of a prescription made in	50
accordance with a consult agreement;	51
(3) As an incident to research, teaching activities, or	52
chemical analysis;	53
(4) In anticipation of orders for drugs pursuant to	54
prescriptions, based on routine, regularly observed dispensing	55
patterns;	56
(5) Pursuant to a request made by a licensed health	57
professional authorized to prescribe drugs for a drug that is to	58
be used by the professional for the purpose of direct	59
administration to patients in the course of the professional's	60
practice, if all of the following apply:	61
(a) At the time the request is made, the drug is not	62
commercially available regardless of the reason that the drug is	63
not available, including the absence of a manufacturer for the	64
drug or the lack of a readily available supply of the drug from	65
a manufacturer.	66
(b) A limited quantity of the drug is compounded and	67
provided to the professional.	68
(c) The drug is compounded and provided to the	69
professional as an occasional exception to the normal practice	70

of dispensing drugs pursuant to patient-specific prescriptions.	71
(D) "Consult agreement" means an agreement to manage an-	72
individual's drug therapy that has been entered into by a	73
pharmacist and a physician authorized under Chapter 4731. of the	74
Revised Code to practice medicine and surgery or osteopathic	75
medicine and surgeryunder section 4729.39 of the Revised Code.	76
(E) "Drug" means:	77
(1) Any article recognized in the United States	78
pharmacopoeia and national formulary, or any supplement to them,	79
intended for use in the diagnosis, cure, mitigation, treatment,	80
or prevention of disease in humans or animals;	81
(2) Any other article intended for use in the diagnosis,	82
cure, mitigation, treatment, or prevention of disease in humans	83
or animals;	84
(3) Any article, other than food, intended to affect the	85
structure or any function of the body of humans or animals;	86
(4) Any article intended for use as a component of any	87
article specified in division (E)(1), (2), or (3) of this	88
section; but does not include devices or their components,	89
parts, or accessories.	90
(F) "Dangerous drug" means any of the following:	91
(1) Any drug to which either of the following applies:	92
(a) Under the "Federal Food, Drug, and Cosmetic Act," 52	93
Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, the drug is	94
required to bear a label containing the legend "Caution: Federal	95
law prohibits dispensing without prescription" or "Caution:	96
Federal law restricts this drug to use by or on the order of a	97
licensed veterinarian" or any similar restrictive statement, or	98

the drug may be dispensed only upon a prescription;	99
(b) Under Chapter 3715. or 3719. of the Revised Code, the	100
drug may be dispensed only upon a prescription.	101
(2) Any drug that contains a schedule V controlled	102
substance and that is exempt from Chapter 3719. of the Revised	103
Code or to which that chapter does not apply;	104
(3) Any drug intended for administration by injection into	105
the human body other than through a natural orifice of the human	106
body.	107
(G) "Federal drug abuse control laws" has the same meaning	108
as in section 3719.01 of the Revised Code.	109
(H) "Prescription" means a written, electronic, or oral	110
order for drugs or combinations or mixtures of drugs to be used	111
by a particular individual or for treating a particular animal,	112
issued by a licensed health professional authorized to prescribe	113
drugs.	114
(I) "Licensed health professional authorized to prescribe	115
drugs" or "prescriber" means an individual who is authorized by	116
law to prescribe drugs or dangerous drugs or drug therapy	117
related devices in the course of the individual's professional	118
practice, including only the following:	119
(1) A dentist licensed under Chapter 4715. of the Revised	120
Code;	121
(2) A clinical nurse specialist, certified nurse-midwife,	122
or certified nurse practitioner who holds a certificate to	123
prescribe issued under section 4723.48 of the Revised Code;	124
(3) An optometrist licensed under Chapter 4725. of the	125
Revised Code to practice optometry under a therapeutic	126

pharmaceutical agents certificate;	127
(4) A physician authorized under Chapter 4731. of the	128
Revised Code to practice medicine and surgery, osteopathic	129
medicine and surgery, or podiatric medicine and surgery;	130
(5) A physician assistant who holds a certificate to	131
prescribe issued under Chapter 4730. of the Revised Code;	132
(6) A veterinarian licensed under Chapter 4741. of the	133
Revised Code.	134
(J) "Sale" and "sell" include delivery, transfer, barter,	135
exchange, or gift, or offer therefor, and each such transaction	136
made by any person, whether as principal proprietor, agent, or	137
employee.	138
(K) "Wholesale sale" and "sale at wholesale" mean any sale	139
in which the purpose of the purchaser is to resell the article	140
purchased or received by the purchaser.	141
(L) "Retail sale" and "sale at retail" mean any sale other	142
than a wholesale sale or sale at wholesale.	143
(M) "Retail seller" means any person that sells any	144
dangerous drug to consumers without assuming control over and	145
responsibility for its administration. Mere advice or	146
instructions regarding administration do not constitute control	147
or establish responsibility.	148
(N) "Price information" means the price charged for a	149
prescription for a particular drug product and, in an easily	150
understandable manner, all of the following:	151
(1) The proprietary name of the drug product;	152
(2) The established (generic) name of the drug product:	153

182

(3) The strength of the drug product if the product	154
contains a single active ingredient or if the drug product	155
contains more than one active ingredient and a relevant strength	156
can be associated with the product without indicating each	157
active ingredient. The established name and quantity of each	158
active ingredient are required if such a relevant strength	159
cannot be so associated with a drug product containing more than	160
one ingredient.	161
(4) The dosage form;	162
(5) The price charged for a specific quantity of the drug	163
product. The stated price shall include all charges to the	164
consumer, including, but not limited to, the cost of the drug	165
product, professional fees, handling fees, if any, and a	166
statement identifying professional services routinely furnished	167
by the pharmacy. Any mailing fees and delivery fees may be	168
stated separately without repetition. The information shall not	169
be false or misleading.	170
(O) "Wholesale distributor of dangerous drugs" means a	171
person engaged in the sale of dangerous drugs at wholesale and	172
includes any agent or employee of such a person authorized by	173
the person to engage in the sale of dangerous drugs at	174
wholesale.	175
(P) "Manufacturer of dangerous drugs" means a person,	176
other than a pharmacist, who manufactures dangerous drugs and	177
who is engaged in the sale of those dangerous drugs within this	178
state.	179
(Q) "Terminal distributor of dangerous drugs" means a	180
person who is engaged in the sale of dangerous drugs at retail,	181

or any person, other than a wholesale distributor or a

211

pharmacist, who has possession, custody, or control of dangerous	183
drugs for any purpose other than for that person's own use and	184
consumption, and includes pharmacies, hospitals, nursing homes,	185
and laboratories and all other persons who procure dangerous	186
drugs for sale or other distribution by or under the supervision	187
of a pharmacist or licensed health professional authorized to	188
prescribe drugs.	189
(R) "Promote to the public" means disseminating a	190
representation to the public in any manner or by any means,	191
other than by labeling, for the purpose of inducing, or that is	192
likely to induce, directly or indirectly, the purchase of a	193
dangerous drug at retail.	194
(S) "Person" includes any individual, partnership,	195
association, limited liability company, or corporation, the	196
state, any political subdivision of the state, and any district,	197
department, or agency of the state or its political	198
subdivisions.	199
(T) "Finished dosage form" has the same meaning as in	200
section 3715.01 of the Revised Code.	201
(U) "Generically equivalent drug" has the same meaning as	202
in section 3715.01 of the Revised Code.	203
(V) "Animal shelter" means a facility operated by a humane	204
society or any society organized under Chapter 1717. of the	205
Revised Code or a dog pound operated pursuant to Chapter 955. of	206
the Revised Code.	207
(W) "Food" has the same meaning as in section 3715.01 of	208
the Revised Code.	209
(X) "Pain management clinic" has the same meaning as in	210

section 4731.054 of the Revised Code.

Sec. 4729.281. (A) A pharmacist may dispense or sell a	212
dangerous drug, other than a schedule II controlled substance as	213
defined in section 3719.01 of the Revised Code, without a	214
written or oral prescription from a licensed health professional	215
authorized to prescribe drugs if all of the following conditions	216
are met:	217
(1) The pharmacy at which the pharmacist works has a	218
record of a prescription for the drug in the name of the patient	219
who is requesting it, but the prescription does not provide for	220
a refill or the time permitted by rules adopted by the state	221
board of pharmacy for providing refills has elapsed.	222
(2) The pharmacist is unable to obtain authorization to	223
refill the prescription from the health care professional who	224
issued the prescription or another health professional	225
responsible for the patient's care.	226
(3) In the exercise of the pharmacist's professional	227
<pre>judgment:</pre>	228
(a) The drug is essential to sustain the life of the	229
patient or continue therapy for a chronic condition of the	230
patient.	231
(b) Failure to dispense or sell the drug to the patient	232
could result in harm to the health of the patient.	233
(4) The (a) Except as provided in division (A) (4) (b) of	234
this section, the amount of the drug that is dispensed or sold	235
under this section does not exceed a seventy-two-hour supply as	236
provided in the prescription.	237
(b) (i) Subject to division (A) (4) (b) (ii) of this section,	238
if the drug dispensed or sold under this section is not a	239
controlled substance and the patient has been on a consistent	240

269

<u>drug therapy as demonstrated by records maintained by a</u>	241
pharmacy, the amount of the drug dispensed or sold does not	242
exceed a thirty-day supply as provided in the prescription or,	243
if the standard unit of dispensing for the drug exceeds a	244
thirty-day supply, the amount of the drug dispensed or sold does	245
not exceed the standard unit of dispensing. The pharmacist shall	246
exercise professional judgment in determining the amount of the	247
drug to be dispensed or sold.	248
(ii) A pharmacist shall not dispense or sell a particular	249
drug to the same patient in an amount described in division (A)	250
(4) (b) (i) of this section more than once in any twelve-month	251
period.	252
(B) A pharmacist who dispenses or sells a drug under this	253
section shall do all of the following:	254
(1) For one year after the date of dispensing or sale,	255
maintain a record in accordance with this chapter of the drug	256
dispensed or sold, including the name and address of the patient	257
and the individual receiving the drug, if the individual	258
receiving the drug is not the patient, the amount dispensed or	259
sold, and the original prescription number;	260
(2) Notify the health professional who issued the	261
prescription described in division (A)(1) of this section or	262
another health professional responsible for the patient's care	263
not later than seventy-two hours after the drug is sold or	264
dispensed;	265
(3) If applicable, obtain authorization for additional	266
dispensing from one of the health professionals described in	267
division (B)(2) of this section.	268

(C) A pharmacist who dispenses or sells a drug under this

frequency of administration, or route of administration;

Page 11

297

Am. H. B. No. 188

(iii) Discontinuing the use of a drug;	298
(iv) Administering a drug;	299
(v) Notwithstanding the definition of "licensed health	300
professional authorized to prescribe drugs" in section 4729.01	301
of the Revised Code, adding a drug to the patient's drug	302
therapy.	303
(b)(i) Order blood and urine tests and evaluate results	304
related to the drug therapy being managed.	305
(ii) A pharmacist's authority to evaluate blood and urine	306
tests under division (B)(1)(b)(i) of this section does not	307
authorize the pharmacist to make a diagnosis.	308
(B) All of the following apply to a consult agreement that	309
authorizes a pharmacist to manage the drug therapy of an-	310
individual who is not a patient of a hospital, as defined in	311
section 3727.01 of the Revised Code, or a resident in a long-	312
term care facility, as defined in section 3729.01 of the Revised	313
<del>Code:</del>	314
(1) A separate consult agreement must be entered into for	315
each individual whose drug therapy is to be managed by a	316
pharmacist. A consult agreement applies only to the particular-	317
diagnosis for which a physician prescribed an individual's drug-	318
therapy. If a different diagnosis is made for the individual,	319
the pharmacist and physician must enter into a new or additional	320
consult agreement.	321
(2) Management of an individual's drug therapy by a	322
pharmacist under a consult agreement may include monitoring and	323
modifying a prescription that has been issued for the	324
individual. Except as provided in section 4729.38 of the Revised	325
Code for the selection of generically equivalent drugs,	326

management of an individual's drug therapy by a pharmacist under	327
a consult agreement shall not include dispensing a drug that has-	328
not been prescribed by the physician.	329
(3) Each consult agreement shall be in writing, except	330
that a consult agreement may be entered into verbally if it is	331
immediately reduced to writing.	332
(4) A physician entering into a consult agreement shall	333
specify in the agreement the extent to which the pharmacist is	334
authorized to manage the drug therapy of the individual	335
specified in the agreement.	336
(5) A physician entering into a consult agreement may	337
specify one other physician who has agreed to serve as an-	338
alternate physician in the event that the primary physician is	339
unavailable to consult directly with the pharmacist. The	340
pharmacist may specify one other pharmacist who has agreed to	341
serve as an alternate pharmacist in the event that the primary	342
pharmacist is unavailable to consult directly with the	343
<del>physician.</del>	344
(6) A consult agreement may not be implemented until it	345
has been signed by the primary pharmacist, the primary	346
physician, and the individual whose drug therapy will be managed	347
or another person who has the authority to provide consent to	348
treatment on behalf of the individual. Once the agreement is	349
signed by all required parties, the physician shall include in	350
the individual's medical record the fact that a consult	351
agreement has been entered into with a pharmacist.	352
(7) Prior to commencing any action to manage an	353
individual's drug therapy under a consult agreement, the	354
pharmacist shall make reasonable attempts to contact and confer-	355

with the physician who entered into the consult agreement with	356
the pharmacist. A pharmacist may commence an action to manage an-	357
individual's drug therapy prior to conferring with the physician-	358
or the physician's alternate, but shall immediately cease the-	359
action that was commenced if the pharmacist has not conferred-	360
with either physician within forty-eight hours.	361
A pharmacist acting under a consult agreement shall	362
maintain a record of each action taken to manage an individual's	363
drug therapy. The pharmacist shall send to the individual's	364
physician a written report of all actions taken to manage the	365
individual's drug therapy at intervals the physician shall-	366
specify when entering into the agreement. The physician shall	367
include the pharmacist's report in the medical records the	368
physician maintains for the individual.	369
(8) (2) (a) A consult agreement, or the portion of the	370
agreement that applies to a particular patient, may be	371
terminated by either the any of the following:	372
(i) A pharmacist or who entered into the agreement;	373
(ii) A physician who entered into the agreement. By	374
withdrawing consent, the individual:	375
(iii) A patient whose drug therapy is being managed or	376
the;	377
(iv) An individual who consented to the treatment on	378
behalf of the individual may terminate a consult agreementa	379
patient or an individual authorized to act on behalf of a	380
patient.	381
The (b) The pharmacist or physician who receives the	382
individual's withdrawal of consent notice of a patient's	383
termination of the agreement shall provide written notice to the	384

opposite partyevery other pharmacist or physician who is a party	385
to the agreement. A pharmacist or physician who terminates a	386
consult agreement with regard to one or more patients shall	387
provide written notice to the opposite party all other	388
pharmacists and physicians who entered into the agreement and to	389
the each individual who consented to treatment under the	390
agreement. The termination of a consult agreement with regard to	391
one or more patients shall be recorded by the pharmacist and	392
physician in the <u>medical</u> records they maintain on the individual	393
being treated of each patient to whom the termination applies.	394
(9) Except as described in division (B)(5) of this	395
section, the authority of a pharmacist to manage an individual's	396
drug therapy under a consult agreement does not permit the	397
pharmacist to manage drug therapy prescribed by any other-	398
physician.	399
(C) All of the following apply to a consult agreement that	400
authorizes a pharmacist to manage the drug therapy of an	401
individual who is a patient of a hospital, as defined in section-	402
3727.01 of the Revised Code, or a resident in a long-term care-	403
facility, as defined in section 3729.01 of the Revised Code:	404
(1) Before a consult agreement may be entered into and	405
implemented, a hospital or long-term care facility shall adopt a	406
policy for consult agreements. For any period of time during	407
which a pharmacist or physician acting under a consult agreement	408
is not physically present and available at the hospital or	409
facility, the policy shall require that another pharmacist and	410
physician be available at the hospital or facility.	411
(2) The (3) A consult agreement shall be made in writing	412
and shall comply with the hospital's or facility's policy on	413
consult agreements include all of the following:	414

(a) The diagnoses and diseases being managed under the	415
agreement, including whether each disease is primary or	416
<pre>comorbid;</pre>	417
(b) A description of the drugs or drug categories the	418
agreement involves;	419
(c) A description of the procedures, decision criteria,	420
and plan the pharmacist is to follow in acting under a consult	421
<pre>agreement;</pre>	422
(d) A description of how the pharmacist is to comply with	423
divisions (B) (5) and (6) of this section.	424
$\frac{(3)-(4)}{(4)}$ The content of the a consult agreement shall be	425
communicated to the individual each patient whose drug therapy	426
will be is managed in a manner consistent with the hospital's or	427
facility's policy on consult agreements under the agreement.	428
(4) A pharmacist acting under a consult agreement	429
shall maintain in the individual's medical record a record of	430
each action taken for each patient whose drug therapy is managed	431
under the agreement.	432
(5) (6) Communication between a pharmacist and physician	433
acting under the a consult agreement shall take place at regular	434
intervals specified by the primary physician acting under the	435
agreement. The agreement may include a requirement that a	436
pharmacist send a consult report to each consulting physician.	437
(6) A consult agreement may be terminated by the	438
individual, a person authorized to act on behalf of the	439
individual, the primary physician acting under the agreement, or	440
the primary pharmacist acting under the agreement. When a	441
consult agreement is terminated, all parties to the agreement	442
shall be notified and the termination shall be recorded in the	443

individual's medical record.	444
(7) The authority of a pharmacist acting under a A consult	445
agreement is effective for two years and may be renewed if the	446
conditions specified in division (A) of this section are met.	447
(8) A consult agreement does not permit the a pharmacist	448
to act under the agreement in a hospital long-term care facility-	449
at which the pharmacist is not authorized to practice manage drug	450
therapy prescribed by a physician who has not entered into the	451
agreement.	452
$\frac{(D)-(C)}{(C)}$ The state board of pharmacy, in consultation with	453
the state medical board, shall adopt rules to be followed by	454
pharmacists, and the state medical board, in consultation with	455
the state board of pharmacy, shall adopt rules to be followed by	456
physicians, that establish standards and procedures for entering	457
into a consult agreement and managing an individual's a	458
<pre>patient's drug therapy under a consult agreement. The boards</pre>	459
shall specify in the rules any categories of drugs or types of	460
diseases for which a consult agreement may not be established.	461
Either board may adopt any other rules it considers necessary	462
for the implementation and administration of this section. All	463
rules adopted under this division shall be adopted in accordance	464
with Chapter 119. of the Revised Code.	465
(D) (1) Subject to division (D) (2) of this section, both of	466
the following apply:	467
(a) A pharmacist acting in accordance with a consult	468
agreement regarding a physician's change in a drug for a patient	469
whose drug therapy the pharmacist is managing under the	470
agreement is not liable in damages in a tort or other civil	471
action for injury or loss to person or property allegedly	472

arising from the change.	473
(b) A physician acting in accordance with a consult	474
agreement regarding a pharmacist's change in a drug for a	475
patient whose drug therapy the pharmacist is managing under a	476
consult agreement is not liable in damages in a tort or other	477
civil action for injury or loss to person or property allegedly	478
arising from the change unless the physician authorized the	479
specific change.	480
(2) Division (D)(1) of this section does not limit a	481
physician's or pharmacist's liability in damages in a tort or	482
other civil action for injury or loss to person or property	483
allegedly arising from actions that are not related to the	484
physician's or pharmacist's change in a drug for a patient whose	485
drug therapy is being managed under a consult agreement.	486
Section 2. That existing sections 4729.01, 4729.281, and	487
4729.39 of the Revised Code are hereby repealed.	488

Page 18